Subscribe to our Email Alerts

Amplia Therapeutics Limited

Amplifying the effect of immuno-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumours

Learn more
 
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Company Overview

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
read more

Latest Corporate Presentation

read more

Our Technology

Innate has an exclusive worldwide licence to develop and commercialise two best-in-class FAK inhibitors (FAKi) developed by the Cancer CRC : AMP945 and AMP886
read more

ASX Share Price

Market Cap:
Price Delay ~20min
read more